Loading...
Search for: glypican
0.009 seconds

    Screening of glypican-6 expression in benign, primary and metastatic colon cancers

    , Article Clinical Medicine Insights: Oncology ; Volume 15 , 2021 ; 11795549 (ISSN) Al Saraireh, Y. M ; Alshammari, F. O. F. O ; Youssef, A. M. M ; Al Sarayreh, S ; Al Sarayra, Y. M ; Aborajooh, E ; Al Shuneigat, J ; Alrawashdeh, H. M ; Sharif University of Technology
    SAGE Publications Ltd  2021
    Abstract
    Background: The development of colon cancer has been described as a multistep process of carcinogenesis. Understanding molecular and cellular changes underlying this process is required to determine potential biomarkers and therapeutic targets in colon cancers. Several molecular entities, including glypicans, are implicated in cancer development. Among these is glypican-6, which is overexpressed in a limited number of cancers. This study aims to characterise the glypican-6 expression in different types of colon cancer. Methods: Immunohistochemistry was used to characterise glypican-6 expression in a panel of archived formalin-fixed, paraffin-embedded colon tissue types. These types included... 

    Glypican-1 overexpression in different types of breast cancers

    , Article OncoTargets and Therapy ; Volume 14 , 2021 , Pages 4309-4318 ; 11786930 (ISSN) Alshammari, F. O. F. O ; Al Saraireh, Y. M ; Youssef, A. M. M ; Al Sarayra, Y. M ; Alrawashdeh, H. M ; Sharif University of Technology
    Dove Medical Press Ltd  2021
    Abstract
    Purpose: Treatment of metastatic breast cancer patients is challenging and remains a major underlying cause of female mortality. Understanding molecular alterations in tumor development is critical to identify novel biomarkers and targets for cancer diagnosis and therapy. One of the aberrant cancer expressions gaining recent research interest is glypican-1. Several studies reported strong glypican-1 expression in various types of human cancers. However, none of these investigated glypican-1 expression in a large cohort of breast cancer histopathological subtypes. Patients and Methods: Immunohistochemistry was used to assess glypican-1 expression in 220 breast cancer patients and its relation...